for successful and effective cytologic screening. It is critical to train the relevant health care professionals-smear takers (physicians, nurses, midwives), smear readers (cytotechnologists), cytopathologists, colposcopists and program managersfor attitudes as well as practices like the issues of the report by Singh and colleagues, to ensure adequate quality of the cytologic smear. Funding should be also enough to provide efficient and high-quality laboratory services, and referral system to ensure that women with an abnormal cytology could attend for management and follow-up. Additional important issues are the priority age group to be screened, the definition of an abnormality to be treated, and the timing of subsequent screening based on nationwide budget for the public health care system [8] .
Second, Nuranna et al. [6] reported successfully implemented See and Treat program as a promising way to screen and treat precancerous lesion of the uterine cervix in low-resource setting. The technical and financial limitations of cytologic screening in low-resource settings have led to the evolution of alternative screening tests such as visual inspection of the uterine cervix with 3-5% acetic acid (VIA). Even though VIA is limited by low specificity of <85% and lack of standardization of quality control, it is simple, inexpensive, low-technology method, no laboratories to report, real-time availability of results, better compliance and a short training period of less than 2 weeks. Thus, VIA could be attractive alternatives to cytologic screening and be more readily integrated into primary health care systems in low-resource settings.
Molecular and epidemiologic studies have consistently shown that the majority of uterine cervical cancers are caused by persistent infections with high-risk types of human papillomavirus (HPV). Current HPV DNA test can detect the presence [9, 10] . Thus, despite uncertain cost-benefit effect and low specificity especially in younger women, HPV DNA tests could be attractive alternatives to cytologic screening programs. In this sight, HPV prophylactic vaccines seem to be fancy and crucial to control uterine cervical cancer. However, the application of HPV vaccine into public health care system may be difficult and impossible in low-resource settings because of high costs. Thus, HPV prophylactic vaccines cannot replace screening for control of uterine cervical cancer.
Cytology should be the gold standard approach as screening strategies of uterine cervical cancer. However, VIA could be attractive alternatives to cytologic screening with substantial promise in low-resource settings. HPV DNA test also could be the preferred approach, if its cost and the laboratories are available. Importantly, screening strategies of uterine cervical cancer should be planned, organized and operated within the context of nationwide program for cancer control.
